

Short Telomeres and a T-Cell Shortfall in COVID-19: The Aging Effect

James J. Anderson¹, Ezra Susser^{2,3}, Konstantin G. Arbeev⁴,
Anatoliy I. Yashin⁴, Daniel Levy^{5,6}, Simon Verhulst⁷, Abraham Aviv⁸

¹School of Aquatic and Fishery Sciences, University of Washington, Seattle, Washington, 98195 USA

²Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY 10032, USA

³New York State Psychiatric Institute, New York, NY, 10032 USA

⁴Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, North Carolina, 27705 USA

⁵Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, 27705 USA

⁶The Framingham Heart Study, Framingham, Massachusetts, 01702 USA

⁷Groningen Institute for Evolutionary Life Sciences, University of Groningen, Groningen, The Netherlands

⁸The Center of Human Development and Aging, New Jersey Medical School, Rutgers University, Newark, New Jersey, 07103 USA

Acknowledgments

AIY and KGA research is supported by NIH grant RF1AG046860. SV human telomere research is funded NIH grant 5U24AG066528. AA telomere research is supported by NIH grants R01 HL134840, U01AG066529 and a grant from the Norwegian Research Council (NFR) ES562296.

Disclaimer: The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services.

Abstract

Transient lymphopenia is a common feature of acute viral respiratory infections¹. The drastic and prolonged lymphopenia of COVID-19, however, is distinctive and largely stems from falling counts of T cells²⁻⁵. This T-cell lymphopenia may contribute to the inordinate rise in COVID-19 mortality with older age⁶, because naïve T-cell clonal expansion is telomere length (TL)-dependent⁷ and TL of hematopoietic cells shortens with age⁸. Here we present a biologically plausible model that links naïve T-cell clonal expansion capacity and age-dependent hematopoietic cell TL (HCTL) shortening to explain the T-cell shortfall and the high COVID-19 mortality in older adults. The model shows that an individual with average HCTL at age twenty years maintains maximal T-cell clonal expansion capacity until the 6th decade of life when this capacity plummets by more than 90% over the next eight years. The collapse coincides with the steep increase in COVID-19 mortality with age. As young adults tend to maintain their relative HCTL over their life course⁹, individuals with above and below average HCTL respectively experience the drop in maximal T-cell clonal expansion capacity at older and younger ages. HCTL metrics may thus explain the vulnerability of older adults to COVID-19 and predict the capacity for T-cell clonal expansion following vaccination against the virus.

The slow pace of global vaccination and the rapid emergence of SARS-CoV-2 variants suggest recurrent waves of COVID-19 in coming years¹⁰. Therefore, understanding why deaths from COVID-19 are highly concentrated among older adults is essential for global health, in particular for countries with a demography skewed towards older age. Declining immunity with advancing age is a general explanation⁶ but the increased mortality from COVID-19 in older adults exceeds that for most viral illnesses and it thus requires specific explanations. One of these might be diminished ability with age to offset the development of and recovery from severe T-cell lymphopenia that often complicates COVID-19²⁻⁵.

Much about the primary etiology of COVID-19 T-cell lymphopenia remains unknown, but regardless of its causes, offsetting the decline in T-cell count during SARS-CoV-2 infection demands fast and massive T-cell clonal expansion, which is telomere length (TL)-dependent⁷. This might explain recent studies that associate short hematopoietic cell TL (HCTL) with low lymphocyte count^{11,12} and severe disease¹³⁻¹⁵ in COVID-19 patients.

The T-cell blood pool size depends on a balance between T-cell depletion, due to senescence/death and sequestration out of the circulation, and T-cell repletion through T-cell proliferation. In absence of an acute infection, the T cell turnover is slow because of the relatively long biological half-lives of naïve T cells and memory T cells, i.e., ~ 5 years and ~ 5 months, respectively¹⁶. In the context of COVID-19 lymphopenia, however, diminished T-cell proliferation in older adults and other individuals with short HCTL could result in a shortfall between T-cell depletion and repletion¹². Moreover, the clearance of SARS-CoV-2 requires clonal expansion and differentiation of naïve T cells into SARS-CoV-2 antigen-specific memory T cells^{2,3,5}. Short naïve T-cell telomeres might thus limit adaptive immunity against the

virus even without a clinical manifestation of T-cell lymphopenia. Making reasonable assumptions, we therefore modelled the relationships of TL-dependent T- cell clonal expansion with age.

The Model

Note: Abbreviations, symbols and units used in the mathematical development and testing the model are presented in Box 1.

The following assumptions on T-cell replication and clone size (CS) drive our model (Fig. 1): (i) T-cell TL-dependent cessation of replication is defined by a

Box 1. Abbreviations, meanings, units and values	
TL ₂₀	TL at age at 20 years (kb)
TL _x	TL at x years older than 20 years (kb)
TL _B	Telomeric brink, stopping cell replication Set at 5 kb in the model
TL ₀	TL at onset of clone size limitation Set at 6.4 kb in the model
X ₀	Age in years when TL ₀ is reached
CS	Clone Size
MCS	Maximal Clone Size (~ one million T cells, denoted 10 ⁶)
LCS	Limited Clone Size (< 10 ⁶ T cells)
Δ _{max}	TL shortening required for achieving MCS (~ 1.4 kb)
g	TL shortening rate with age (~ 0.03 kb/year)
r	TL shortening rate per T-cell replication (~ 0.07 kb)
N _{max}	N of T-cell replications to achieve MCS (before TL ₀ , X ₀) 20 replications to produce MCS of ~ 10 ⁶ T cells
N	Number of T-cell replications to achieve LCS (after TL ₀ , X ₀)

“telomeric brink” (TL_B) that stops replication at 5 kilobases⁸. (ii) TL of a naïve T cell at age 20 years (TL₂₀) progressively shortens at a rate g of 0.03 kb/year^{17,18} until it reaches the TL_B. (iii) In exponential growth, i.e., 1 → 2 → 4 → 8 → 16, etc., a single naïve T cell can generate a maximal CS (MCS) of ~ 10⁶ (one million) memory T cells through ~ 20 replications (N_{max}); this value was estimated based on the ~ 1.4 kb TL difference between circulating naïve and memory T cells and the ~ 0.07 kb telomere shortening per replication of cultured T cells¹⁹. (iv) We denote the maximal TL shortening due to clonal expansion as Δ_{max} and the TL shortening per replication as r. (v) Due to age-dependent TL shortening, a naïve T- cell TL reaches the “telomeric onset” (TL₀ = 6.4 kb) at “age of onset” (X₀). (vi) Until X₀, a naïve T cell can generate MCS. After X₀, a naïve T cell can generate only a limited clonal size (LCS < MCS), as the TL of the clonal cells converges to the TL_B. (vii) Most memory T cells are formed in response to new antigens

during childhood and early adulthood²⁰, when HCTL is comparatively long^{21,22}, enabling the achievement of MCS.

We define CS by the number (N) of T-cell replications producing $CS = 2^N$. As a clone expands, TL of its T cells progressively shortens, i.e., $\Delta = rN$, where r is the telomere shortening due to T-cell replication.

Prior to X_0 , the maximum number of T-cell replications in clonal expansion is $N_{\max} = \Delta_{\max} / r = 20$.

After X_0 , the number of T-cell replications in clonal expansion is $N = (TL_X - TL_B) / r$, where X designates age

and the corresponding age-dependent TL of a naïve T cell is $TL_X = TL_{20} - g(X - 20)$, where g is the TL

shortening in the naïve T cell each year. The resulting X_0 is the number of years it takes for a naïve T cell to reach TL_0 . These measures are defined by

$$\begin{aligned} X_0 &= 20 + (TL_{20} - TL_B - \Delta_{\max}) / g \\ TL_0 &= TL_B + \Delta_{\max} \end{aligned} \quad (1)$$

The clone size depends on age relative to the X_0 as follows

$$\begin{aligned} X \leq X_0 & \quad MCS = 2^{N_{\max}} = 2^{\Delta_{\max} / r} \\ X > X_0 & \quad LCS = 2^N = 2^{(TL_{20} - TL_B - g(X - 20)) / r} \end{aligned} \quad (2)$$

The following considerations are relevant for appraising the model's parameters and assumptions: First, while the MCS is based on the *in vivo* TL difference between naïve and memory T cells, the data on telomere shortening per T-cell replication are from cultured cells¹⁹. A similar approach (based on data from circulating hematopoietic cells and telomere shortening in cultured cells) was previously used to generate consistent information on hematopoietic cell replicative kinetics^{23,24}. Second, the model's TL parameters are derived from a large population-based study⁸ that measured HCTL by Southern blotting²⁵. Its telomere data are consistent with another large-scale study that used Flow-FISH to measure HCTL²⁶. Third, the model is based on age-dependent shortening of HCTL and not T-cell TL. As TL differences among leukocyte lineages within the individual are far smaller than the inter-individual HCTL variation²⁷, T-cell TL largely mirrors HCTL. Fourth, the TL signal for cessation of cell replication

originates from the shortest telomeres in the nucleus and not their mean TL^{28,29}. Using the Telomeres Shortest Length Assay (TeSLA), a method that tallies and measures the shortest telomeres³⁰, we recently showed that in patients with COVID-19 the shortest telomeres in peripheral blood mononuclear cells were associated with low lymphocyte counts¹¹. The principles that drive our model thus likely apply to the T cell's shortest telomeres.

Results

Consider three individuals with average, long (one SD above the mean) and short (one SD below the mean) naïve T-cell TL₂₀ (Fig. 2a): Their naïve T-cells display a slow pace of shortening at a rate of 0.030 kb/year (Fig. 2b). Up to X₀ of 50 years (TL₀ = 6.4 kb), the naïve T cells of the individual with the average TL₂₀ can attain the MCS of ~10⁶ T cells. Thereafter, however, the ability of these naïve T cells to clonally expand plummets from the MCS to 0.5 x 10⁶, 0.25 x 10⁶ and 0.125 x 10⁶ T cells at ages 53, 55 and 57 years, respectively (Fig. 2c). Next consider the individual with long T-cell TL₂₀ (Fig. 2a). The ability of naïve T-cells of this individual to achieve MCS extends to the X₀ of 70 years (TL₀ = 6.4 kb) (Fig. 2c). This suggests that even among older adults, some individuals can develop MCS when infected by SARS-CoV-2. In contrast, naïve T cells of the individual with short T-cell TL₂₀ are able to achieve MCS only until the X₀ of 30 years (TL₀ = 6.4 kb) (Fig. 2c), inferring that some young adults might generate a poor T-cell response to SARS-CoV-2 infection. A three-dimensional configuration of the effect of age on T-cell TL and CS dynamics is displayed in Fig. S1, Supplementary Information A.

Our model thus suggests that in the overwhelming majority of the general population, naïve T cells can achieve MCS before early adulthood. Later, post X₀, while age-dependent shortening of T-cell telomeres remains slow (Fig. 2b), it has a striking effect on clonal expansion of naïve T cells because the exponential nature of the process (Fig. 2c). As SARS-CoV-2 memory T cells play a greater role than neutralizing antibodies in recovering from the infection⁵, such an effect could impede adaptive immunity

and heighten the risk for severe COVID-19. Moreover, we assume that MCS of $\sim 10^6$ T cells applies not only for naïve T cells that clonally expand to produce memory T cells but also naïve T cells that clonally expand to produce naïve T cells. This means that regardless of the primary cause of COVID-19 T-cell lymphopenia, the T cell response will be compromised post X_0 .

With aging, T cells of an increasing proportion of the population reach X_0 (Fig. 3a). After reaching this TL landmark, LCS contracts to less than 10% of MCS during the course of 8 years and to 1% over 16 years. This rapid LCS contraction means that at any age, the vast majority of individuals separate into two sub-populations; those with naïve T cells that can generate MCS and those with naïve T cells that can only generate LCS, which a few years after X_0 is a small fraction of MCS. While naïve T cells of individuals in their twenties can overwhelmingly generate MCS, naïve T cells of the majority of individuals in their seventies can at best generate clones that are typically less than one tenth of MCS (Fig. 3b).

What then might be the minimal TL-dependent T-cell CS that enables survival of an individual contracting COVID-19? The definitive answer can only come from telomere and T-cell data in a large population of COVID-19 patients. That said, we infer this CS based on Centers for Disease Control and Prevention (CDC) reports of the age-specific COVID-19 mortality rates for the United States³¹ and the population size by age in 2019³². We computed an age-dependent hazards ratio of mortality relative to age 20 years (Hazards_{20}) from COVID-19 and from general causes³¹ other than COVID-19 (Methods). The Hazards_{20} yields an exponential increase of COVID-19 mortality with age, and for comparison, we also display Hazards_{20} for mortality from non-COVID-19 causes (Fig. 4a).

We assumed that, as a subpopulation, individuals who generate MCS experience no T-cell TL-related COVID-19 mortality. We therefore calculated the mean CS for the LCS subpopulation only, i.e. adults

older than X_0 (Fig. 3a). The TL-limited clonal expansion of individuals in the LCS subpopulation, we assumed, might contribute to their propensity to die from COVID-19, given the association between lymphopenia and COVID-19 mortality. Figure 4b shows that the mean LCS in adults older than X_0 decreases in a near linear manner with age. Plots of the mean LCS vs. Hazards ratios₂₀ of COVID-19 mortality and non-COVID-19 mortality suggests a divergence between the two trajectories near the start of the 6th decade (Fig. 4c). The figure also displays the mean LCS at the age of 50 years, which corresponds to the age at which the size of LCS subpopulation is similar to that of the MCS subpopulation (Fig. 3b). Mean LCS at this age amounts to $\sim 0.13 \times 10^{-6}$ T cells.

The divergence of COVID-19 mortality from non- COVID-19 mortality when the mean LCS is about one tenth of MCS suggests the following: In the absence of COVID-19, $\sim 10\%$ MCS is generally sufficient to accommodate the low turnover of T-cells¹⁶. This LCS, however, might contribute to mortality in the face of SARS-CoV-2, because the infection demands massive T-cell clonal expansion to offset the primary cause of the dropping naïve T-cell count, and to generate memory T-cells that clear the virus.

Discussion

With the exception of heritability³³, no other single factor so profoundly affects HCTL as does aging, explaining the key conclusion of our model. As illustrated in Figs. 2,3, our model also applies to naïve T cells of a small subset of younger adults, whose HCTL is ranked at the lower range of the HCTL distribution^{8,26}. Specific groups might have diminished naïve T-cell clonal expansion in response to SARS-CoV-2 infection because of comparatively shorter HCTL. These include males, whose HCTL is shorter than in females from birth onwards²¹. These groups also include persons with atherosclerotic cardiovascular disease³⁴, obese persons³⁵ and smokers^{36,37}, whose HCTL is respectively shorter than that

in healthy, lean and non-smoking individuals. All these groups are at a higher risk of severe COVID-19 and death from the disease³⁸⁻⁴¹.

Humans have comparatively short telomeres relative to their long lifespan⁴², and therefore our model may not apply to most terrestrial mammals, including laboratory animal models that are used for viral research. For instance, TL-mediated replicative aging is probably not consequential during the 2-3- year lifespan of mice, considering their long telomeres (mean TL > 30 kb) and robust telomerase activity in their somatic cells⁴²⁻⁴⁴. In contrast, the average human TL at birth is only ~ 9.5 kb²¹. As telomerase activity is repressed in replicating human somatic cells⁴²⁻⁴⁴, their short telomeres experience further age-dependent shortening after birth. Although naïve T cells have some telomerase activity^{7,19}, it is insufficient to prevent their age-dependent telomere shortening, and aging may thus undermine the T-cell clonal expansion in many humans.

After reaching X_0 , our model predicts that naïve T cells will stall in generating through clonal expansion not only antigen-specific memory T cells but also new naïve T cells. Two converging lines of evidence support this idea: The numbers of naïve CD8 T cells decline with age⁴⁵. As a low count of naïve CD8 T cells contributes to severe COVID-19⁵, individuals with short HCTL might thus be at a heightened risk for severe disease. Second, whereas lymphopenia is a major prognostic feature of COVID-19 in adults, when present, it is transient and of little prognostic value in children⁴⁶⁻⁴⁹. The longer HCTL during early life potentially explain this clinical course.

Relatedly, the model shows that naïve T-cells with TL_{20} of one SD below the mean are unable to achieve MCS as early as after the third decade of life. This unexpected finding suggests that (a) under-estimation of naïve T- cell TL using population-based HCTL data, or (b) in response to pathogens, more

naïve T cells might be tapped for clonal expansion⁵⁰ in young adults with short T-cell telomeres. Older adults may not have sufficient naïve T cells, particularly, naïve CD8 T cells, for this purpose⁴⁵.

We acknowledge the following limitations: Our model is deterministic with fixed rates and thresholds selected as best estimates from available literature. That said, analysis of the effects of assumptions on the LCS definition and uncertainty in the parameters r , g , TL_B and Δ_{max} indicate that the TL_0 and X_0 exhibit little error from the LCS assumption and parameter uncertainties. (Supplementary Information B2). The model draws on HCTL data from populations comprising principally whites of European ancestry in high-income countries. It should also be tested in populations of different ancestries and in low- and middle-income countries. The TL difference between naïve T cells and memory T cells likely reflects the clonal expansion in response to not only a single encounter but multiple encounters with a given antigen and its cross-reactive antigens. Thus, the MCS and LCS definitions in absolute T-cell numbers might be off the mark. Of note, however, the MCS and LCS can be expressed in the model in relative units of MCS (i.e., 0.5 MCS, 0.25 MCS, etc.) rather than absolute units (i.e., 0.5×10^6 , 0.25×10^6 T cells, etc.), yielding identical results to those based on absolute T-cell numbers. Therefore, the principles of our model are likely to hold notwithstanding the above limitations.

In conclusion, the age-dependent TL effect on naïve T-cell clonal expansion likely influences the outcome of SARS-CoV-2 infection. The insight generated by our model might set the stage for measurement of TL parameters not only in older adults but also the general adult population, helping to identify individuals vulnerable to severe COVID-19 because of short T-cell telomeres. These individuals might also be less likely to develop a lasting T-cell-mediated immunity in response to anti-SARS-CoV-2 vaccines. Finally, the ramifications of these conclusions go beyond the influence of TL on T-cell response to SARS Cov-2 infection and vaccination against the virus. They suggest that TL might be a limiting factor

in immunotherapies whose efficacies depend on clonally expanding (in vivo and in vitro) transplanted hematopoietic cells, chimeric antigen receptor T cells, and tumor-infiltrating lymphocytes.

Methods

The relationships between the age-dependent T-cell TL density and the relative proportion of CS in a population (Fig. 3) were derived from the distribution of HCTL at age twenty, extrapolated from age-specific density plots of HCTL⁸. In Fig. 3a, the T-cell TL distribution for age 20 was derived from 1,000,000 random generations from a normal distribution with a mean = 7.3 kb and SD = 0.6 kb.

The combined male and female hazards ratios relative to age 20 in Fig. 4a were calculated from age-specific COVID-19-linked mortalities and total non-COVID-19 linked mortalities normalized by the age-specific US population. The, $\text{Hazards}_{20} = \left(\text{mortality}_{age} / \text{population}_{age} \right) / \left(\text{mortality}_{20} / \text{population}_{20} \right)$, are based on the CDC records of 494,234 provisional COVID-19 deaths and 3,845,819 total deaths between January 1, 2020 through March 8, 2021³¹ and the 2019 US Census³². Non-COVID-19 mortalities were estimated by subtracting the COVID-19 mortalities from the total mortalities for each age group.

The definition of the LCS subpopulation sets the MCS at which TL-dependent COVID-19 mortality can occur. The LCS subpopulation includes any CS < MCS. Correspondingly, other definitions, i.e., cutoff levels, for the category, e.g., LCS < 0.5 MCS or LCS < 0.15 MCS, result in different relationships of mean LCS with age and Hazards₂₀. Supplementary information B2 explores the effects of these alternative LCS cutoff levels on Figs. 3 and 4. Lower cutoff levels have minor effects on which histogram bars in Fig. 3 are assigned to the LCS and MCS subpopulations. For Fig. 4b, lower cutoff levels reduce the mean LCS at age 20 years but not at age 80 years. Consequently, the relation of mean LCS with age is nearly linear for all LCS cutoff levels. Lower cutoff levels reduce the range of the mean LCS scale, i.e., rescales the x axis (Fig. 4c). In essence, this rescaling does not change the relative shape of the Hazards₂₀ curves for both

COVID-19 and non-COVID-19 mortalities, but does change the LCS values at which the two curves diverge. This change does not impact, therefore, the model's qualitative response with age.

Furthermore, the uncertainty in the absolute value of CS is mitigated by expressing LCS as a fraction of the MCS. Finally, the LCS is not used for developing Fig. 2.

Codes for generating the figures are provided in Supplementary Information C.

References

1. McClain, M.T., Park, L.P., Nicholson B, Veldman T, Zaas AK, Turner R, Lambkin-Williams R, Gilbert AS, Ginsburg GS, Woods CW. Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections. *J Clin Virol.* **58**, 689-95 (2013).
2. Sette, A., Crotty, S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell.* **12**, S0092-8674(21)00007-6. doi: 10.1016/j.cell.2021.01.007. Online ahead of print. PMID: 33497610 (2021).
3. Chen Z, John Wherry E. T cell responses in patients with COVID-19. *Nat Rev Immunol.* 2020 Sep;20(9):529-536. doi: 10.1038/s41577-020-0402-6. Epub 2020 Jul 29. PMID: 32728222
4. Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, Yuan Z, Feng Z, Zhang Y, Wu Y and Chen Y (2020) Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). *Front. Immunol.* 11:827. doi: 10.3389/fimmu.2020.00827
5. Rydzynski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, Belanger S, Abbott RK, Kim C, Choi J, Kato Y, Crotty EG, Kim C, Rawlings SA, Mateus J, Tse LPV, Frazier A, Baric R, Peters B, Greenbaum J, Ollmann Saphire E, Smith DM, Sette A, Crotty S. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease

- Severity. *Cell*. 2020 Nov 12;183(4):996-1012.e19. doi: 10.1016/j.cell.2020.09.038. Epub 2020 Sep 16. PMID: 33010815
6. Promislow DEL. A Geroscience Perspective on COVID-19 Mortality. *J Gerontol A Biol Sci Med Sci*. 2020 Sep 16;75(9):e30-e33. doi: 10.1093/gerona/glaa094. PMID: 32300796
 7. Patrick M, Weng NP. Expression and regulation of telomerase in human T cell differentiation, activation, aging and diseases. *Cell Immunol*. 2019 Nov; 345:103989. doi: 10.1016/j.cellimm.2019.103989. Epub 2019 Sep 19. Review. PMID: 31558266
 8. Steenstrup T, Kark JD, Verhulst S, Thinggaard M, Hjelmberg JVB, Dalgård C, Kyvik KO, Christiansen L, Mangino M, Spector TD, Petersen I, Kimura M, Benetos A, Labat C, Sinnreich R, Hwang SJ, Levy D, Hunt SC, Fitzpatrick AL, Chen W, Berenson GS, Barbieri M, Paolisso G, Gadalla SM, Savage SA, Christensen K, Yashin AI, Arbeevev KG, Aviv A. Telomeres and the natural lifespan limit in humans. *Aging (Albany NY)*. 2017 Apr;9(4):1130-1142. doi: 10.18632/aging.101216. PMID: 28394764
 9. Benetos A, Kark JD, Susser E, Kimura M, Sinnreich R, Chen W, Steenstrup T, Christensen K, Herbig U, von Bornemann Hjelmberg J, Srinivasan SR, Berenson GS, Labat C, Aviv A. Tracking and fixed ranking of leukocyte telomere length across the adult life course. *Aging Cell*. 2013 Aug;12(4):615-21. doi: 10.1111/accel.12086. Epub 2013 May 27. PMID: 23601089
 10. Murray CJL, Piot P. The Potential Future of the COVID-19 Pandemic: Will SARS-CoV-2 Become a Recurrent Seasonal Infection? *JAMA*. Published online March 03, 2021. doi:10.1001/jama.2021.2828
 11. Benetos A, Lai TP, Toupance S, Labat C, Verhulst S, Gautier S, Ungeheuer MN, Perret-Guillaume C, Levy D, Susser E, Aviv A. The Nexus between Telomere Length and Lymphocyte Count in Seniors hospitalized with COVID-19. *J Gerontol A Biol Sci Med Sci*. 2021 Feb 2:glaa026. doi: 10.1093/gerona/glaa026. Online ahead of print. PMID: 33528568

12. Aviv A. Telomeres and COVID-19. *FASEB J.* 2020 Jun;34(6):7247-7252. doi: 10.1096/fj.202001025. Epub 2020 May 19. PMID: 32427393
13. Qingning Wang, Veryan Codd, Zahra Raisi-Estabragh, Crispin Musicha, Vasiliki Bountziouka, Stephen Kaptoge, Elias Allara, Emanuele Di Angelantonio, Adam S. Butterworth, Angela M. Wood, John R. Thompson, Steffen E Petersen, Nicholas C. Harvey, John N. Danesh, Nilesh J. Samani, Christopher P. Nelson. Older biological age is associated with adverse COVID-19 outcomes: A cohort study in UK Biobank. medRxiv 2021.03.20.21254010; doi: <https://doi.org/10.1101/2021.03.20.21254010>
14. Froidure A, Mahieu M, Hoton D, Laterre PF, Yombi JC, Koenig S, Ghaye B, Defour JP, Decottignies A. Short telomeres increase the risk of severe COVID-19. *Aging (Albany NY)*. 2020 Oct 26;12(20):19911-19922. doi: 10.18632/aging.104097. Epub 2020 Oct 26 PMID: 33104521
15. Sanchez-Vazquez R, Guío-Carrión A, Zapatero-Gaviria A, Martínez P, Blasco MA. Shorter telomere lengths in patients with severe COVID-19 disease. *Aging (Albany NY)*. 2021 Jan 11;13(1):1-15. doi: 10.18632/aging.202463. Epub 2021 Jan 11. PMID: 33428591
16. Vrisekoop N, den Braber I, de Boer AB, Ruiter AF, Ackermans MT, van der Crabben SN, Schrijver EH, Spierenburg G, Sauerwein HP, Hazenberg MD, de Boer RJ, Miedema F, Borghans JA, Tesselaar K. Sparse production but preferential incorporation of recently produced naive T cells in the human peripheral pool. *Proc Natl Acad Sci U S A.* 2008 Apr 22;105(16):6115-20. doi: 10.1073/pnas.0709713105. Epub 2008 Apr 17. PMID: 18420820
17. Steenstrup T, Hjelmborg JV, Kark JD, Christensen K, Aviv A. The telomere lengthening conundrum--artifact or biology? *Nucleic Acids Res.* 2013 Jul;41(13):e131. doi: 10.1093/nar/gkt370. Epub 2013 May 13. PMID: 23671336

18. Nettle D, Gadalla SM, Lai TP, Susser E, Bateson M, Aviv A. Telomere length measurement for longitudinal analysis: implications of assay precision. *Am J Epidemiol*. 2021 Feb 10:kwab025. doi: 10.1093/aje/kwab025. Online ahead of print. PMID: 33564874
19. Weng NP, Hathcock KS, Hodes RJ. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. *Immunity*. 1998 Aug;9(2):151-7. doi: 10.1016/s1074-7613(00)80597-x. PMID: 9729035
20. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. *Nat Rev Immunol*. 2014 Jan;14(1):24-35. doi: 10.1038/nri3567. Epub 2013 Dec 13. PMID: 24336101
21. Factor-Litvak P, Susser E, Kezios K, McKeague I, Kark JD, Hoffman M, Kimura M, Wapner R, Aviv A. Leukocyte Telomere Length in Newborns: Implications for the Role of Telomeres in Human Disease. *Pediatrics*. 2016 Apr;137(4):e20153927. doi: 10.1542/peds.2015-3927. Epub 2016 Mar 11. PMID: 26969272
22. Benetos A, Verhulst S, Labat C, Lai TP, Girerd N, Toupance S, Zannad F, Rossignol P, Aviv A. Telomere length tracking in children and their parents: implications for adult onset diseases. *FASEB J*. 2019 Dec;33(12):14248-14253. doi: 10.1096/fj.201901275R. Epub 2019 Oct 25. PMID: 31652401
23. Sidorov I, Kimura M, Yashin A, Aviv A. Leukocyte telomere dynamics and human hematopoietic stem cell kinetics during somatic growth. *Exp Hematol*. 2009 Apr;37(4):514-24. doi: 10.1016/j.exphem.2008.11.009. Epub 2009 Feb 12. PMID: 19216021
24. Shepherd BE, Gutterop P, Lansdorp PM, Abkowitz JL. Estimating human hematopoietic stem cell kinetics using granulocyte telomere lengths. *Exp Hematol*. 2004 Nov;32(11):1040-50. doi: 10.1016/j.exphem.2004.07.023. PMID: 15539081

25. Kimura M, Stone RC, Hunt SC, Skurnick J, Lu X, Cao X, Harley CB, Aviv A. Measurement of telomere length by the Southern blot analysis of terminal restriction fragment lengths. *Nat Protoc.* 2010 Sep;5(9):1596-607. doi: 10.1038/nprot.2010.124. Epub 2010 Sep 2. PMID: 21085125
26. Aubert G, Baerlocher GM, Vulto I, Poon SS, Lansdorp PM. Collapse of telomere homeostasis in hematopoietic cells caused by heterozygous mutations in telomerase genes. *PLoS Genet.* 2012;8(5):e1002696. doi: 10.1371/journal.pgen.1002696. Epub 2012 May 17. PMID: 22661914
27. Kimura M, Gazitt Y, Cao X, Zhao X, Lansdorp PM, Aviv A. Synchrony of telomere length among hematopoietic cells. *Exp Hematol.* 2010 Oct;38(10):854-9. doi: 10.1016/j.exphem.2010.06.010. Epub 2010 Jun 25. PMID: 20600576
28. Hemann MT, Strong MA, Hao LY, Greider CW. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. *Cell.* 2001;107(1):67-77. Epub 2001/10/12. doi: 10.1016/s0092-8674(01)00504-9. PubMed PMID: 11595186.
29. Zou Y, Sfeir A, Gryaznov SM, Shay JW, Wright WE. Does a sentinel or a subset of short telomeres determine replicative senescence? *Mol Biol Cell.* 2004;15(8):3709-18. Epub 2004/06/08. doi: 10.1091/mbc.e04-03-0207. PubMed PMID: 15181152; PMCID: PMC491830.
30. Lai TP, Zhang N, Noh J, Mender I, Tedone E, Huang E, Wright WE, Danuser G, Shay JW. A method for measuring the distribution of the shortest telomeres in cells and tissues. *Nat Commun.* 2017;8(1):1356. Epub 2017/11/09. doi: 10.1038/s41467-017-01291-z. PubMed PMID: 29116081; PMCID: PMC5676791
31. CDC. 2021. Deaths involving coronavirus disease 2019 (COVID-19) reported to NCHS by sex and age group and week ending date. (<https://data.cdc.gov/NCHS/Provisional-COVID-19-Death-Counts-by-Sex-Age-and-W/vsak-wrfu/data>).

32. CB. 2019. 2019: ACS 1-year estimates subject tables. Survey/Program: American Community Survey TableID: S0101. U.S. Census Bureau. (<https://data.census.gov/cedsci/all?q=S0101>).
33. Hjelmberg JB, Dalgård C, Möller S, Steenstrup T, Kimura M, Christensen K, Kyvik KO, Aviv A. The heritability of leucocyte telomere length dynamics. *J Med Genet*. 2015 May;52(5):297-302. doi: 10.1136/jmedgenet-2014-102736. Epub 2015 Mar 13. PMID: 25770094
34. Benetos A, Toupance S, Gautier S, Labat C, Kimura M, Rossi PM, Settembre N, Hubert J, Frimat L, Bertrand B, Boufi M, Flecher X, Sadoul N, Eschwege P, Kessler M, Tzanetakou IP, Doulamis IP, Konstantopoulos P, Tzani A, Korou M, Gkogkos A, Perreas K, Menenakos E, Samanidis G, Vasiloglou-Gkanis M, Kark JD, Malikov S, Verhulst S, Aviv A. Short Leukocyte Telomere Length Precedes Clinical Expression of Atherosclerosis: The Blood-and-Muscle Model. *Circulation Research*. 2018;122(4):616-23. Epub 2017/12/16. doi: 10.1161/circresaha.117.311751. PubMed PMID: 29242238; PMCID: PMC5821479.
35. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, Aviv A, Spector TD. Obesity, cigarette smoking, and telomere length in women. *Lancet*. 2005;366(9486):662-4. Epub 2005/08/23. doi: 10.1016/s0140-6736(05)66630-5. PubMed PMID: 16112303, PMC2810865.
36. Nawrot TS, Staessen JA, Gardner JP, Aviv A. Telomere length and possible link to X chromosome. *Lancet*. 2004 Feb 14;363(9408):507-10. PMID: 14975611
37. Bateson M, Aviv A, Bendix L, Benetos A, Ben-Shlomo Y, Bojesen SE, Cooper C, Cooper R, Deary IJ, Hägg S, Harris SE, Kark JD, Kronenberg F, Kuh D, Labat C, Martin-Ruiz CM, Meyer C, Nordestgaard BG, Penninx BWJH, Pepper GV, Révész D, Said MA, Starr JM, Syddall H, Thomson WM, van der Harst P, Whooley M, von Zglinicki T, Willeit P, Zhan Y, Nettle D. Smoking does not accelerate leucocyte telomere attrition: a meta-analysis of 18 longitudinal cohorts. *R Soc Open Sci*. 2019 Jun 5;6(6):190420. doi: 10.1098/rsos.190420. eCollection 2019 Jun. PMID: 31312500

38. Nimgaonkar I, Valeri L, Susser E, Hussain S, Sunderram J, Aviv A. The age pattern of the male-to-female ratio in mortality from COVID-19 mirrors that of cardiovascular disease in the general population. *Aging (Albany NY)*. 2021 Feb 7;13(3):3190-3201. doi: 10.18632/aging.202639. Epub 2021 Feb 7. PMID: 33550276
39. Bae S, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: a systematic review and meta-analysis. *Heart*. 2021 Mar;107(5):373-380. doi: 10.1136/heartjnl-2020-317901. Epub 2020 Dec 17. PMID: 33334865
40. Popkin BM, Du S, Green WD, Beck MA, Algaith T, Herbst CH, Alsukait RF, Alluhidan M, Alazemi N, Shekar M. Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships. *Obes Rev*. 2020 Nov;21(11):e13128. doi: 10.1111/obr.13128. Epub 2020 Aug 26. PMID: 32845580
41. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. *Nicotine Tob Res*. 2020 Aug 24;22(9):1653-1656. doi: 10.1093/ntr/ntaa082. PMID: 32399563
42. Gomes NMV, Oliver A, Ryder, Marlys L, Houck, Suellen J, Charter, William Walker, Nicholas R. Forsyth, Steven N. Austad, Chris Venditt, Mark Pagel, Jerry W Shay, Woodring E. Wright. Comparative biology of mammalian telomeres: hypotheses on ancestral states and the roles of telomeres in longevity determination. *Aging Cell*. 2011 Oct; 10(5): 761–768. Published online 2011 Jun 1. doi: 10.1111/j.1474-9726. PMID: PMC3387546
43. Calado RT, Dumitriu B. Telomere dynamics in mice -and humans. *Semin Hematol*. 2013 Apr;50(2):165-74. doi: 10.1053/j.seminhematol.2013.03.030. PMID: 23956466
44. Zhang F, Cheng D, Wang S, Zhu J. Human Specific Regulation of the Telomerase Reverse Transcriptase Gene. *Genes (Basel)*. 2016 Jun 28;7(7):30. doi: 10.3390/genes7070030. PMID: 27367732

45. Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. *Nat Rev Immunol*. 2019 Sep;19(9):573-583. doi: 10.1038/s41577-019-0180-1. Epub 2019 Jun 11. PMID: 31186548; PMCID: PMC7584388.
46. Du H, Dong X, Zhang JJ, Cao YY, Akdis M, Huang PQ, Chen HW, Li Y, Liu GH, Akdis CA, Lu XX, Gao YD. Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status. *Allergy*. 2020 Jun 10:10.1111/all.14452. doi: 10.1111/all.14452. Online ahead of print. PMID: 32524611
47. Ma X, Liu S, Chen L, Zhuang L, Zhang J, Xin Y. The clinical characteristics of pediatric inpatients with SARS-CoV-2 infection: A meta-analysis and systematic review. *J Med Virol*. 2020 Jun 19:10.1002/jmv.26208. doi: 10.1002/jmv.26208. Online ahead of print. PMID: 32558955
48. Wu H, Zhu H, Yuan C, Yao C, Luo W, Shen X, Wang J, Shao J, Xiang Y. Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. *JAMA Netw Open*. 2020 Jun 1;3(6):e2010895. doi: 10.1001/jamanetworkopen.2020.10895. PMID: 32492165
49. Zachariah P, Johnson CL, Halabi KC, Ahn D, Sen AI, Fischer A, Banker SL, Giordano M, Manice CS, Diamond R, Sewell TB, Schweickert AJ, Babineau JR, Carter RC, Fenster DB, Orange JS, McCann TA, Kernie SG, Saiman L; Columbia Pediatric COVID-19 Management Group. Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children's Hospital in New York City, New York. *JAMA Pediatr*. 2020 Jun 3:e202430. doi: 10.1001/jamapediatrics.2020.2430. Online ahead of print. PMID: 32492092
50. Mayer A, Zhang Y, Perelson AS, Wingreen NS. Regulation of T cell expansion by antigen presentation dynamics. *Proc Natl Acad Sci U S A*. 2019 Mar 26;116(13):5914-5919. doi:




Fig. 1 | Age-dependent T-cell telomere length (TL) before (—) and after (—) clonal expansion. Naïve T-cell clonal expansion shortens telomeres by Δ , where Δ_{max} is T-cell telomere shortening resulting from expansion to form the maximal clonal size (MCS). The telomeric brink (TL_B) of 5 kb is TL that increases the risk of cessation of replication. TL_{20} is TL at 20 years, TL_0 is telomeric onset, which indicates the shortest T-cell TL that enables attaining MCS. X_0 is age of onset of clonal expansion limitation.




Fig. 2 | Population distribution of T-cell TL at age 20 (TL_{20}) (a), T-cell TL shortening with age (b), and age-dependent change in T-cell clone size (CS) (c). a displays the TL_{20} distribution, showing mean TL = 7.3 kb (—), long TL (mean + SD) = 7.9 kb (—), and short TL (mean - SD) = 6.7 kb (—). **b** displays age-dependent change in T-cell for mean, long and short TL_{20} . Past the telomeric onset ($TL_0 = 6.4$ kb), TL is insufficient to produce MCS because a full clonal expansion drops TL below the telomeric brink ($TL_B = 5$ kb). The TL_0 is reached at different ages of onset (X_0), i.e., an older age for T-cells with long T-cell telomeres and younger with T-cells with short telomeres. The age-dependent T-cell TL shortening (0.030 kb/year) for T cells with mean, long and short telomeres at TL_{20} is shown by the lines. **c** shows that the T-cell CS is partitioned by the X_0 into plateau and slope regions. T cells with mean, long or short TL_{20} achieve MCS on the CS plateau, but their CS exponentially collapses (slope) once their TLs shorten below TL_0 of 6.4 kb and exceed X_0 (at different ages).




Fig. 3 | Shifts by age in naïve T-cell TL distribution (a) and relative frequency (0 to 10) of T-cell clone size (CS) (b) in the population. **a** displays the shift in TL_{20} distribution (Fig. 2a) resulting from age-dependent shortening of 0.030 kb/year. It depicts $TL < TL_0$ (6.4 kb) by blue bars (■) and $TL > TL_0$ by red bars (■). **b** displays relative frequency of CS's generated by naïve T-cell clonal expansion corresponding to the categories of TL below or above TL_0 . It shows that maximal CS (MCS) of $\sim 10^6$ cells occurs in individuals with naïve T-cell $TL > TL_0$, while limited CS (LCS) occurs in those with naïve T-cell $TL \leq TL_0$. At age 20, naïve T cells of nine out of ten individuals can generate MCS. At age 70, naïve T cells of less than two out of ten individuals can generate MCS, and seven out of ten generate clone sizes that are less than 0.1 MCS. At age 50 the population is approximately equally divided between the MCS and LCS groups.




Fig. 4 | Steps linking mean limited clone size (LCS) to COVID-19 mortality and general mortality Hazards ratios₂₀ in the population. **a** displays data based on COVID-19 mortality (●) and non- COVID-19 mortality (●), and corresponding exponential fitted relationships for Hazards ratios₂₀ (— and —). **b** displays the relationship of mean LCS in units of 10^6 cells with age, generated with equation 2, using the TL₂₀ distribution of Fig. 2a. **c** displays the relationships of Hazards ratios₂₀ generated from COVID-19 mortality and non-COVID-19 mortality plotted against mean LCS obtained from **b**. The top of the panel also displays age. The divergence between the COVID-19 and non-COVID-19 mortalities occurs at mean LCS of $\sim 0.13 \times 10^6$ T cells. At the corresponding age, 50 years, the population is about evenly divided into the LCS and MCS sub-populations (Fig. 3b). After this age, the majority of the population is in the LCS group, which is susceptible to COVID-19 mortality, whereas the MCS group is not.